Relying on a global supply chain system, we can consistently to provide stable and reliable radioisotopes. At the same time, we have developed a variety of new nuclide generators, which can effectively alleviate the supply shortage of short half-life radioisotopes in the market.
Relying on a global supply chain system, we can consistently to provide stable and reliable radioisotopes. At the same time, we have developed a variety of new nuclide generators, which can effectively alleviate the supply shortage of short half-life radioisotopes in the market.
We are developing a series of molecularly targeted products for the diagnosis and treatment of cancer, that will redefine the next generation of radiopharmaceuticals based on product and technology innovations.
View moreMissouri radioisotope producer MURR joins European nuclear medicine group
Conventional and next-generation imaging evaluation of biochemically recurrent prostate cancer
Pharmaceuticals & Radiopharmaceuticals for Image-Guided Robotic Surgery
SNMMI Image of the Year: Ultra-High-Resolution PET Provides Never Before Seen Images of the Brain
SNMMI Abstract of the Year: [177Lu]Lu-PSMA-617 Extends Progression-Free Survival with Manageable Safety Profile in Taxane-Naïve Advanced Prostate Cancer Patients
Aktis Oncology and Lilly to discover and develop novel anticancer radiopharmaceuticals